Adipokine Response, Brain-Derived Neurotrophic Factor (BDNF), Cognitive Function, Exercise Physiology, Irisin, Omentin-1
Conditions
Keywords
Boxer, Athletes, Jackfruit, Irisin, Omentin-1, BDNF, Cognitive Performance, Anthropometric Measurements, Adipokines, Trail Making Test, Wisconsin Card Sorting Test (WCST), Body Composition
Brief summary
This study investigates the effects of jackfruit oil extract on adipokine levels (Irisin, Omentin-1), brain-derived neurotrophic factor (BDNF), cognitive performance, and body measurements in healthy young boxers aged 18-25. Participants were randomly assigned to four groups receiving different doses of jackfruit oil extract (0, 100, 200, 300 mg/kg) or no supplement. Saliva samples, cognitive tests, and body measurements were collected at the start of the study and after 30 days to evaluate the outcomes.
Detailed description
This interventional study evaluates the effects of different doses of jackfruit oil extract on healthy young boxers aged 18-25. Participants were randomly assigned to four groups and followed for 30 days. Saliva samples were collected to measure irisin, omentin-1, and BDNF levels. Cognitive performance was assessed using the Wisconsin Card Sorting Test and the Trail Making Test. Anthropometric parameters including weight, BMI, waist, hip, chest, limb circumferences, and body composition were measured at baseline and on day 30. Statistical analyses were performed using SPSS version 26. ANOVA, Duncan, and Pearson correlation tests were used to determine significant differences and relationships between variables. This study is randomized and controlled. Participants receive either one of three doses of jackfruit oil extract or no supplement. The follow-up period is 30 days.
Interventions
DIETARY_SUPPLEMENTJackfruit Supplement
Participants in the experimental group will receive a daily dose of jackfruit supplement during the study period. The supplement is administered orally and standardized for bioactive components. Participants in the control group will not receive any jackfruit supplement.
Sponsors
Bayburt University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
Participants were randomly assigned to four parallel groups (J0, J100, J200, J300) receiving different doses of jackfruit oil extract (0, 100, 200, 300 mg/kg). Each group received the assigned intervention for 30 days, and outcomes including salivary irisin, omentin-1, BDNF levels, cognitive performance, and anthropometric measurements were assessed at baseline and at the end of the intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Male boxers aged 18-25 years * Healthy individuals without any diagnosed chronic disease * Participating in regular weekly boxing training * Able to continue training throughout the study period * Willing to voluntarily participate in the study * Able to provide written and/or verbal informed consent
Exclusion criteria
* Presence of chronic diseases (e.g., diabetes, cardiovascular disorders) * Any injury or musculoskeletal condition preventing continuation of training * Known allergy or hypersensitivity to jackfruit or its components * Use of medications or supplements that could interfere with study outcomes * Individuals who refuse to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Salivary Irisin Level | Day 0 and Day 30 | Irisin levels measured from saliva samples collected from participants using the ELISA method. |
| Salivary Omentin-1 Level | Day 0 and Day 30. | Omentin-1 levels measured from saliva samples collected from participants using the ELISA method. |
| Salivary BDNF Level | Day 0 and Day 30. | BDNF levels measured from saliva samples collected from participants using the ELISA method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Waist Circumference (cm) | Day 0 and Day 30 | Waist circumference measured with a flexible tape measure. |
| Hip Circumference (cm) | Day 0 and Day 30 | Hip circumference measured with a flexible tape measure. |
| Chest Circumference (cm) | Day 0 and Day 30 | Chest circumference measured using a flexible tape measure. |
| Biomarker Correlations (Irisin-Omentin-BDNF vs. Dose/Day) | Based on Day 30 measurements | Pearson correlation analysis examining relationships between biomarkers and intervention dose/day. |
| Upper Arm Circumference (Right/Left, cm) | Day 0 and Day 30 | Right and left upper arm circumferences measured with a flexible tape measure. |
| Wrist Circumference (Right/Left, cm) | Day 0 and Day 30 | Right and left wrist circumferences measured with a flexible tape measure. |
| Thigh Circumference (Right/Left, cm) | Day 0 and Day 30 | Right and left thigh circumferences measured with a flexible tape measure. |
| Calf Circumference (Right/Left, cm) | Day 0 and Day 30 | Right and left calf circumferences measured with a flexible tape measure. |
| Total Body Fat Mass (kg) | Day 0 and Day 30 | Total body fat mass measured using Tanita BC-418. |
| Total Body Fat Percentage (%) | Day 0 and Day 30 | Total body fat percentage measured using Tanita BC-418. |
| Abdominal Fat Mass (kg) | Day 0 and Day 30 | Abdominal fat mass measured using Tanita BC-418. |
| Regional Fat Percentages (Right/Left Arm & Leg) | Day 0 and Day 30 | Regional fat percentages for arms and legs measured by Tanita BC-418. |
| Body Weight (kg) | Day 0 and Day 30 | Body weight measured using Tanita BC-418 bioimpedance device. |
| Regional Muscle Mass (Right/Left Arm & Leg, kg) | Day 0 and Day 30 | Regional muscle mass of arms and legs measured by Tanita BC-418. |
| Basal Metabolic Rate (BMR) | Day 0 and Day 30 | Basal metabolic rate calculated by Tanita BC-418. |
| Metabolic Age | Day 0 and Day 30 | Metabolic age estimated using Tanita BC-418 device. |
| Total Body Water (kg) | Day 0 and Day 30 | Total body water measured via bioimpedance analysis. |
| Total Body Water Percentage (%) | Day 0 and Day 30 | Total Body Water Percentage (%) |
| WCST Total Correct Responses | Day 0 and Day 30 | Total correct responses obtained from the Wisconsin Card Sorting Test. |
| WCST Total Incorrect Responses | Day 0 and Day 30 | Total incorrect responses measured using the Wisconsin Card Sorting Test. |
| WCST Perseverative Error Count | Day 0 and Day 30 | Perseverative errors recorded during the Wisconsin Card Sorting Test. |
| WCST Total Time (seconds) | Day 0 and Day 30 | Total time required to complete the Wisconsin Card Sorting Test. |
| Trail Making Test A Completion Time (seconds) | Day 0 and Day 30 | Completion time for Trail Making Test Part A. |
| Trail Making Test B Completion Time (seconds) | Day 0 and Day 30 | Completion time for Trail Making Test Part B. |
| Safety Outcomes (Adverse Event Monitoring) | Continuous monitoring throughout 30 days | Monitoring of potential adverse events related to 300 mg/kg JOE administration. |
| Total Muscle Mass (kg) | Day 0 and Day 30 | Total muscle mass assessed using Tanita BC-418. |
| Height (cm) | Day 0 and Day 30 | Height measured using a standard stadiometer. |
| Body Mass Index (kg/m²) | Day 0 and Day 30 | BMI calculated using the formula weight (kg)/height (m²). |
Countries
Turkey (Türkiye)
Outcome results
None listed